The National Comprehensive Cancer Network (NCCN) has recommended the use of GE HealthCare’s Cerianna fluoroestradiol F18 (FES) positron emission tomography (PET) imaging agent for ER+ breast cancer.
The updated NCCN guidelines suggested that clinicians and patients can use FES PET for estrogen receptor-positive (ER+) disease in certain situations.
FES PET can be utilised during the systemic staging of recurrent or metastatic breast cancer patients.
The company’s Cerianna injection, which is being marketed in the US, is claimed to be the only FES PET imaging agent approved by the US Food and Drug Administration (FDA).
NCCN updated the guidelines following the publication of Appropriate Use Criteria by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) to provide guidance regarding the use of ER-targeted PET imaging with 16α-18F-fluoro-17ß Fluoroestradiol.
GE HealthCare’s pharmaceutical diagnostics segment chief medical officer Dr Mark Hibberd said: “We are delighted to see the inclusion of Cerianna PET in the NCCN breast oncology guidelines, for potential use when oncologists are evaluating metastatic breast cancer patients.
“Detecting ER+ lesions in patients with recurrent or metastatic breast cancer could potentially aid oncologists, surgeons and clinicians in choosing the most appropriate therapy for patients.”
Cerianna is designed for use along with PET imaging to support the detection of ER+ lesions as supplementary to biopsy in recurring or metastatic breast cancer patients.
It provides a complete overview of ER+ lesions, helping in making informed diagnoses and treatment plans for patients.
Furthermore, this approach is expected to offer a more targeted and personalised treatment strategy and help avoid inappropriate or less-effective therapies.